איסלנד -
איסלנדית -
LYFJASTOFNUN (Icelandic Medicines Agency)
biphozyl (calfodil) blóðskilunar-/blóðsíunarlausn 22 mmól/l
baxter holding b.v.* - magnesii chloridum; natrii chloridum; sodium hydrogen carbonate; kalii chloridum; dinatrii hydrogenophosphas - blóðskilunar-/blóðsíunarlausn - 22 mmól/l
איסלנד -
איסלנדית -
LYFJASTOFNUN (Icelandic Medicines Agency)
gaviscon tuggutafla
nordic drugs ab - aluminium hydroxide; sodium hydrogen carbonate; acidum alginicum - tuggutafla
איסלנד -
איסלנדית -
LYFJASTOFNUN (Icelandic Medicines Agency)
ibandronic acid wh filmuhúðuð tafla 150 mg
williams & halls ehf - ibandronate sodium monohydrate - filmuhúðuð tafla - 150 mg
איסלנד -
איסלנדית -
LYFJASTOFNUN (Icelandic Medicines Agency)
rescueflow stungulyf/innrennslislyf, lausn 60/75 g/l
oresund pharma aps - dextran 70; sodium chloride - stungulyf/innrennslislyf, lausn - 60/75 g/l
האיחוד האירופי -
איסלנדית -
EMA (European Medicines Agency)
sugammadex piramal
piramal critical care b.v. - sugammadex sodium - taugakerfi - sugammadex - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.
האיחוד האירופי -
איסלנדית -
EMA (European Medicines Agency)
sugammadex adroiq
extrovis eu ltd. - sugammadex sodium - taugakerfi - Öll önnur lækningavörur - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
איסלנד -
איסלנדית -
LYFJASTOFNUN (Icelandic Medicines Agency)
sugammadex hameln stungulyf, lausn 100 mg/ml
hameln pharma gmbh - sugammadex sodium - stungulyf, lausn - 100 mg/ml
האיחוד האירופי -
איסלנדית -
EMA (European Medicines Agency)
ammonaps
immedica pharma ab - járn phenylbutyrate - ornithine carbamoyltransferase deficiency disease; citrullinemia; carbamoyl-phosphate synthase i deficiency disease - Önnur meltingarvegi og efnaskipti vörur, - ammonaps er fram eins og venjulega meðferð í langvarandi stjórnun súrefnismettun hringrás vandamál, þar munar carbamylphosphate lígasa, tilfærslu rna orargininosuccinate lígasa. Það er ætlað í alla sjúklinga með nýbura-upphaf kynningu (heill ensím galla, kynna innan fyrsta 28 daga af lífi). Það er einnig ætlað í sjúklinga með seint-upphaf sjúkdómur(hluta ensím galla, kynna eftir fyrsta mánuðinn líf) sem hafa sögu af hyperammonaemic heilabólgu.
האיחוד האירופי -
איסלנדית -
EMA (European Medicines Agency)
pheburane
eurocept international b. v. - járn phenylbutyrate - karbamóýl-fosfórinn Þétti Ég skort sjúkdómur - Ýmsum meltingarvegi og efnaskipti vörur - meðferð langvarandi stjórnun súrefnismettun-hringrás sjúkdóma.
האיחוד האירופי -
איסלנדית -
EMA (European Medicines Agency)
xyrem
ucb pharma ltd - natríumoxýbat - cataplexy; narcolepsy - Önnur lyf í taugakerfinu - meðferð við narkólsi með kataplexi hjá fullorðnum sjúklingum.